SMMT
Summit Therapeutics Inc.
$16.62
-0.85
(-4.87%)
Mkt Cap
12.89B
Volume
6,845,082
52W Range
13.83-30.98
Sector
Healthcare
Beta
-1.25
EPS (TTM)
-1.40
P/E Ratio
-12.11
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 583,190 | 1.34M | 628,875 | 611,872 | 57.09M | 14.17M | 2.38M | 1.28M | 1.89M |
| Net Income | (1.08B) | (176.77M) | (482.37M) | (65.17M) | (65.52M) | (38.53M) | (23.99M) | 10.87M | (20.16M) | (21.37M) | (24.34M) | (17.12M) |
| EPS | -1.44 | -0.25 | -0.78 | -0.34 | -0.71 | -0.55 | -0.73 | 0.11 | -0.31 | -0.35 | -0.34 | -0.31 |
| Free Cash Flow | (240.15M) | (113.67M) | (60.85M) | (34.41M) | (54.03M) | (35.65M) | (15.83M) | (35.27M) | (21.26M) | 15.07M | N/A | N/A |
| FCF / Share | -0.32 | -0.16 | -0.10 | -0.18 | -0.59 | -0.51 | -0.48 | -0.41 | -0.33 | 0.25 | N/A | N/A |
| Operating CF | (239.67M) | (113.56M) | (60.74M) | (33.90M) | (53.81M) | (35.34M) | (15.56M) | (35.11M) | (20.58M) | 15.18M | N/A | N/A |
| Total Assets | 557.50M | 348.05M | 160.60M | 541.43M | 84.04M | 75.29M | 75.46M | 79.53M | 78.10M | 46.98M | N/A | N/A |
| Total Debt | 15.50M | 5.77M | 83.96M | 422.89M | 2.06M | 341,545 | 674,116 | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 167.18M | 83.79M | 56.52M | 284.18M | 53.22M | 48.78M | 49.96M | 35.23M | 28.45M | 35.08M | N/A | N/A |
| Book Value | 488.98M | 310.64M | 61.48M | 103.25M | 61.74M | 58.36M | 61.12M | 55.79M | (4.46M) | (4.37M) | N/A | N/A |
| Return on Equity | -2.21 | -0.57 | -7.85 | -0.63 | -1.06 | -0.66 | -0.39 | 0.19 | N/A | N/A | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (189.42M) | (219.17M) | (231.79M) | (412.15M) | (48.70M) | (48.89M) | (42.08M) | (47.77M) | (34.45M) | (28.68M) | (17.43M) | (11.59M) |
| EPS | -0.24 | -0.29 | -0.31 | -0.56 | -0.07 | -0.07 | -0.06 | -0.07 | -0.05 | -0.04 | -0.03 | -0.02 |
| Free Cash Flow | (92.93M) | (75.78M) | (69.24M) | (48.97M) | (47.70M) | (38.91M) | (23.16M) | (26.12M) | (24.01M) | (15.40M) | (12.29M) | (23.13M) |
| FCF / Share | -0.12 | -0.10 | -0.09 | -0.07 | -0.07 | -0.06 | -0.03 | -0.04 | -0.03 | -0.02 | -0.02 | -0.03 |
| Operating CF | (92.74M) | (75.65M) | (69.19M) | (48.97M) | (47.38M) | (38.89M) | (23.11M) | (26.07M) | (24.01M) | (15.40M) | (12.25M) | (23.11M) |
| Total Assets | 491.31M | 557.50M | 194.56M | 237.76M | 297.29M | 348.05M | 383.65M | 270.07M | 140.83M | 160.60M | 179.59M | 187.39M |
| Total Debt | 15.20M | 15.50M | 4.03M | 4.07M | 5.00M | 5.77M | 24.79M | 85.88M | 87.25M | 83.96M | 87.67M | 84.67M |
| Cash & Equiv | 80.78M | 167.18M | 177.33M | 218.56M | 163.84M | 83.79M | 71.54M | 22.46M | 48.83M | 56.52M | 19.56M | 33.25M |
| Book Value | 414.01M | 488.98M | 142.92M | 190.36M | 266.70M | 310.64M | 334.11M | 154.11M | 35.22M | 61.48M | 81.69M | 94.42M |
| Return on Equity | -0.46 | -0.45 | -1.62 | -2.17 | -0.18 | -0.16 | -0.13 | -0.31 | -0.98 | -0.47 | -0.21 | -0.12 |
SMMT News
Here's Why You Should Add SMMT Stock to Your Portfolio Now
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
Cancer Stocks That Are Advancing the Future of Oncology Care
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Summit Therapeutics Stock Dips After Q1 Financial Report
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio?
SMMT Stock Up 24% in Three Months: Here's What You Need to Know